Terlipressin in the treatment of late phase catecholamine-resistant septic shock.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16170%2F12%3A43871655" target="_blank" >RIV/62157124:16170/12:43871655 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.5754/hge10550" target="_blank" >http://dx.doi.org/10.5754/hge10550</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5754/hge10550" target="_blank" >10.5754/hge10550</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Terlipressin in the treatment of late phase catecholamine-resistant septic shock.

Popis výsledku v původním jazyce

BACKGROUND/AIMS: Norepinephrine, but also dopamine and epinephrine are recommended as first line vasopressors in the treatment of septic shock. In some patients, septic shock deteriorates and becomes to be resistant to catecholamines. In this situation,addition of vasopressin or terlipressin can be advantageous. The aim of our pilot study was to evaluate the impact of terlipressin on open label norepinephrine requirements and mortality. METHODOLOGY: In a randomized, controlled, single centre study we assigned patients with late advanced septic shock refractory to catecholamines (norepinephrine }0.6?g/kg/min for more than 24h) to receive either continuously terlipressin 4mg/24h for 72 hours in addition to open label norepinephrine (TERLI group) or to continue therapy only with catecholamines (CON group). All vasopressor infusions were titrated to maintain a target blood pressure. RESULTS: We enrolled 30 patients, of whom 13 were assigned to terlipressin and in 17 we continued in catech

Název v anglickém jazyce

Terlipressin in the treatment of late phase catecholamine-resistant septic shock.

Popis výsledku anglicky

BACKGROUND/AIMS: Norepinephrine, but also dopamine and epinephrine are recommended as first line vasopressors in the treatment of septic shock. In some patients, septic shock deteriorates and becomes to be resistant to catecholamines. In this situation,addition of vasopressin or terlipressin can be advantageous. The aim of our pilot study was to evaluate the impact of terlipressin on open label norepinephrine requirements and mortality. METHODOLOGY: In a randomized, controlled, single centre study we assigned patients with late advanced septic shock refractory to catecholamines (norepinephrine }0.6?g/kg/min for more than 24h) to receive either continuously terlipressin 4mg/24h for 72 hours in addition to open label norepinephrine (TERLI group) or to continue therapy only with catecholamines (CON group). All vasopressor infusions were titrated to maintain a target blood pressure. RESULTS: We enrolled 30 patients, of whom 13 were assigned to terlipressin and in 17 we continued in catech

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

GJ - Choroby a škůdci zvířat, veterinární medicina

OECD FORD obor

—

Projekt

<a href="/cs/project/NR9284" target="_blank" >NR9284: Terlipresin v léčbě septického šoku rezistentního na katecholaminy</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hepato-Gastroenterology

ISSN

0172-6390

e-ISSN

—

Svazek periodika

59

Číslo periodika v rámci svazku

116

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

5

Strana od-do

1043-1047

Kód UT WoS článku

000305447400021

EID výsledku v databázi Scopus

—